A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.

被引：0
|
作者：
Furukawa, Masayuki
Ueno, Makoto
Sakai, Daisuke
Ouchi, Kota
Hamamoto, Yasuo
Aikata, Hiroshi
Ozaka, Masato
Tsumura, Hidetaka
Tsuji, Kunihiro
Kubo, Shoji
Nishina, Tomohiro
Katanuma, Akio
Morizane, Chigusa
Ikeda, Masafumi
Mizuno, Nobumasa
Inagaki, Takashi
Shioji, Kazuhiko
Furuse, Junji
机构：
[1] Natl Kyushu Canc Ctr, Fukuoka, Japan
[2] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[3] Osaka Univ, Sch Med, Suita, Osaka, Japan
[4] Tohoku Univ Hosp, Dept Med Oncol, Sendai, Miyagi, Japan
[5] Keio Univ, Sch Med, Div Outpatient Chemotherapy, Ctr Canc, Tokyo, Japan
[6] Hiroshima Univ, Hiroshima, Japan
[7] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
[8] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[9] Ishikawa Prefectural Cent Hosp, Dept Gastroenterol, Kanazawa, Ishikawa, Japan
[10] Osaka Metropolitan Univ, Osaka, Japan
[11] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[12] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Hokkaido, Japan
[13] Natl Canc Ctr, Tokyo, Japan
[14] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[15] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi, Japan
[16] Oita Univ Hosp, Oita, Japan
[17] Niigata Canc Ctr Hosp, Niigata, Japan
[18] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页码：533 / 533
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study
    Zuo, Jin
    Wu, Lingying
    Li, Xiaofan
    Feng, Mei
    Li, Guiling
    Yin, Rutie
    Li, Xiumin
    Kang, Shan
    Sun, Hongmei
    Wei, Shuqing
    Zhang, Yunyan
    Wang, Yili
    Liu, Hu
    Wang, Wei
    Sun, Li
    Zhu, Zhitu
    Lin, Daren
    Jiang, Kui
    Xiang, Silong
    Niu, Miao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma
    Chien-Hsu Chen
    Mu-Yao Tsai
    Ping-Chia Chiang
    Ming-Tse Sung
    Hao-Lun Luo
    Jau-Ling Suen
    Eing-Mei Tsai
    Po-Hui Chiang
    [J]. Cancer Immunology, Immunotherapy, 2021, 70 : 2981 - 2990
  • [3] Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma
    Chen, Chien-Hsu
    Tsai, Mu-Yao
    Chiang, Ping-Chia
    Sung, Ming-Tse
    Luo, Hao-Lun
    Suen, Jau-Ling
    Tsai, Eing-Mei
    Chiang, Po-Hui
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (10) : 2981 - 2990
  • [4] Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2.
    Tsimafeyeu, Ilya
    Musayeva, Gunel
    Samira, Mahmudova
    Otkhozoria, Nana
    Abbasov, Bahadur
    Kahharov, Alisher
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 303 - 303
  • [5] Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
    Zhu, Jue
    Yan, Lifeng
    Wang, Qiming
    [J]. JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [6] Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
    Jue Zhu
    Lifeng Yan
    Qiming Wang
    [J]. Journal of Ovarian Research, 14
  • [7] Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.
    Brown, Landon Carter
    Halabi, Susan
    Humeniuk, Michael Sandon
    Wu Yuan
    Oyekunle, Taofik
    Huang Jiaoti
    Anand, Monika
    Davies, Catrin
    Zhang Tian
    Harrison, Michael Roger
    George, Daniel J.
    Armstrong, Andrew J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
    Lu, S.
    Fang, J.
    Liu, A.
    Dong, X.
    Yu, Y.
    Han, S.
    Zeng, Z.
    Zhang, R.
    Lu, P.
    Shi, H.
    Tan, P.
    Fan, S.
    Shi, M.
    Su, W.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1656 - S1656
  • [9] The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma
    Matsubara, Yuki
    Toriyama, Kazuhiro
    Kadowaki, Shigenori
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Masuishi, Toshiki
    Bando, Hideaki
    Ando, Masashi
    Tajika, Masahiro
    Oze, Isao
    Hosoda, Waki
    Muro, Kei
    [J]. ESOPHAGUS, 2023, 20 (03) : 524 - 532
  • [10] The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma
    Yuki Matsubara
    Kazuhiro Toriyama
    Shigenori Kadowaki
    Takatsugu Ogata
    Taiko Nakazawa
    Kyoko Kato
    Kazuki Nozawa
    Yukiya Narita
    Kazunori Honda
    Toshiki Masuishi
    Hideaki Bando
    Masashi Ando
    Masahiro Tajika
    Isao Oze
    Waki Hosoda
    Kei Muro
    [J]. Esophagus, 2023, 20 : 524 - 532
12345